Clinical Trials Browser

Phase 2 × Recruiting × aflutinib × Clear all

NCT07548060 2026-04-23

TROP-LUNG

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT07304739 2025-12-26

Furmonertinib Combined With Intrathecal Chemotherapy and Stereotactic Radiotherapy (SRT) for EGFR-Mutated NSCLC Patients With Brain Parenchymal and Leptomeningeal Metastases

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung, Meningeal Carcinomatosis

NCT06652048 2025-11-21

High-dose Furmonertinib or Combined With Chemotherapy in EGFR-mutant Advanced NSCLC After Disease Progression on Third-generation EGFR-TKI

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT06962865 2025-07-16

A Phase Ⅱ Study of RC108 in Combination With Furmonertinib for the First-line Treatment of EGFR-Mutated Combined MET-Positive Unresectable Locally Advanced or Recurrent Metastatic NSCLC

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT04322890 2024-10-22

PIKACHU

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT05379803 2024-09-19

High-dose Furmonertinib for First-line Treatment of EGFR Mutated NSCLC With Central Nervous System (CNS) Metastases

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT06394674 2024-07-26

High-dose Furmonertinib in the Treatment in Patients With Advanced, Metastatic NSCLC With Progressed After First- or Second-line Treatment With Osimertinib

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT06192849 2024-01-05

To Assess the Efficacy and Safety of Furmonertinib in Patients With Epidermal Growth Factor Receptor 20ins Mutation Positive Stage IB-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT05445310 2023-02-16

Adjuvant Furmonertinib in Stage IA With High Risk Factors and Stage IB Non-small Cell Lung Cancer

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT05334277 2022-08-31

FOCUS-C

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT05503667 2022-08-17

Neoadjuvant Furmonertinib Plus Bevacizumab or Furmonertinib Monotherapy for Resectable and Potentially Resectable Stage III-IVA EGFR Mutation-Positive Lung Adenocarcinoma

Phase 2 Recruiting

Adenocarcinoma of Lung